China
UCB Divests Mature Neurology and Allergy Portfolio in China for $680M
UCB, China, neurology, allergy, divestment, CBC Group, Mubadala, pharmaceuticals, innovation, strategic partnerships
UCB Divests Chinese Production Plant and Older Medications for $680 Million
UCB, production plant, older medications, China, $680M, pharmaceutical industry, divestment
Astellas Employee Indicted by China’s Prosecutors on Espionage Charges
Astellas Pharma, China, Japan, espionage, indictment, diplomatic tensions
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts
Kyowa Kirin, China business, small-molecule discovery, restructuring, Asia Pacific, pharmaceuticals
China’s Corruption Crackdown Impacts Merck’s Gardasil Sales, Rattling Investors
Merck, Gardasil, China, Corruption Crackdown, Healthcare, Pharmaceuticals, HPV Vaccine
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Innovent Achieves Another Phase 3 Victory in China for Next-Generation Lilly GLP-1 Drug
Innovent Biologics, Lilly, GLP-1, Mazdutide, Phase 3 Trial, Type 2 Diabetes, Weight Loss, China
Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns
Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy